<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440230</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1503</org_study_id>
    <nct_id>NCT02440230</nct_id>
  </id_info>
  <brief_title>Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients</brief_title>
  <acronym>SEAT</acronym>
  <official_title>Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with
      exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of bone or joint pains</measure>
    <time_frame>participants will be followed at 0,3,6,9,12 months from enrollment.</time_frame>
    <description>Bone and joint pains are measured by National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) classification v4.0 every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peri-menapausal syndrome</measure>
    <time_frame>KMI score</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OFS + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFS + Exemestane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFS + Anastrozole</intervention_name>
    <description>Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
Patients will take anastrozole 1mg qd.</description>
    <arm_group_label>OFS + Anastrozole</arm_group_label>
    <other_name>OFS + Ana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFS + Exemestane</intervention_name>
    <description>Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.</description>
    <arm_group_label>OFS + Exemestane</arm_group_label>
    <other_name>OFS + EXE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥18 years;

          2. Histologically confirmed invasive breast cancer by core needle biopsy or
             surgery,hormonal receptor positive, defined as estrogen receptor(ER)/progesterone
             receptor(PR) positive;

          3. Premenopausal defined as

               -  who have been menstruating regularly during the 6 months prior to randomization
                  and have not used any form of hormonal contraception or any other hormonal
                  treatments during the 6 months prior to randomization.

               -  premenopausal status confirmed by an estradiol (E2) in the premenopausal range
                  after chemotherapy related amenorrhea;

          4. Patients must have received standard local therapy: normalized modified radical
             mastectomy or breast conserving surgery with negative margin and post-surgical
             radiotherapy. Patient should completed adjuvant therapy according to conditions,
             including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy;

          5. Patients who did not receive chemotherapy should be randomized within 24 weeks after
             definitive surgery.Patients who received prior adjuvant and/or neoadjuvant
             chemotherapy should be randomized after completing chemotherapy and within 8 months of
             the final dose of chemotherapy as soon as premenopausal status is confirmed;

          6. Leukocyte ≥ 3*109/L; Platelets ≥ 75*109/L; Serum glutamate;

          7. oxaloacetate(AST/SGOT) or serum glutamic-pyruvic transaminase(ALT/SGPT) &lt;2.5 times of
             upper limit of normal (UNL) range;

          8. Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL) range;

          9. Written informed consent according to the local ethics committee requirements.

         10. Has Eastern Cooperative Oncology Group(ECOG) Performance Score 0-2;

        Exclusion Criteria:

          1. Histologically confirmed hormonal receptor negative.

          2. Post-menopausal.

          3. Patients with inoperable local advanced breast cancer including inflammatory breast
             cancer or supraclavicular node involvement or with enlarged internal mammary nodes
             (unless pathologically negative).

          4. Definitive surgery was done over 24 weeks before randomization for patients who did
             not receive chemotherapy.The final dose of chemotherapy was completed over 8 months
             before randomization for patients who received prior adjuvant and/or neoadjuvant
             chemotherapy.

          5. Pregnant or lactating.

          6. Patients with previous or concomitant invasive malignancy are not eligible. The
             exceptions are patients with the following (and only the following) malignancies
             (previous or concomitant) who are eligible if adequately treated: basal or squamous
             cell carcinoma of the skin in situ non-breast carcinoma without invasion contra- or
             ipsilateral in situ breast carcinoma non-breast invasive malignancy diagnosed at least
             5 years ago and without recurrence:

               -  stage I papillary thyroid cancer

               -  stage Ia carcinoma of the cervix

               -  stage Ia or b endometrioid endometrial cancer

               -  borderline or stage I ovarian cancer

          7. Patients who received endocrine therapy (including neoadjuvant and adjuvant) for more
             than 8 months after their breast cancer diagnosis.

          8. Patients who were taking tamoxifen or other selective estrogen receptor modulator
             (SERM,e.g. Raloxifene) or hormone replacement therapy (HRT) within one year prior to
             their breast cancer diagnosis.

          9. Patients who have had a bilateral oophorectomy or ovarian irradiation prior to their
             breast cancer diagnosis.

         10. With severe hepatic dysfunction, Child-Pugh C.

         11. With severe cardiac dysfunction, New York Heart Association (NYHA) grading III or
             worse.

         12. Known severe hypersensitivity to any drugs in this study.

         13. Participants of other experimental drug clinical trials
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiahui Huang, MD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>602215</phone_ext>
    <email>hjh3269@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaosong Chen, MD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>602215</phone_ext>
    <email>chenxiaosong0156@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosong Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kunwei Shen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adjuvant endocrine therapy</keyword>
  <keyword>safety</keyword>
  <keyword>Exemestane</keyword>
  <keyword>ovarian function suppression</keyword>
  <keyword>anastrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

